Biotechnology & Medical Research

Navidea Biopharmaceuticals Inc receives Orphan Drug Designation from FDA for use of Lymphoseek in Head and Neck Cancers

Navidea Biopharmaceuticals Inc:Says that Lymphoseek (technetium Tc 99m tilmanocept) Injection has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for use in sentinel lymph node detection in patients with cancer of the head and neck.Designation is based upon an...

4:07pm EDT

Silver Leaf Oak acquires stake in Biocon Ltd's subsidiary

Biocon Ltd:Says Silver Leaf Oak has agreed to acquire a minority 10 pct stake in Syngene International Ltd, Biocon's Research Services Ltd and wholly owned subsidiary of Biocon Ltd at a valuation of 38 bln Indian Rupees.Post the completion Biocon and BRL will jointly hold 85.54 pct stake in Syngene.

8:22am EDT

ProQR Therapeutics BV announces pricing of Initial Public Offering

ProQR Therapeutics BV:Announces the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share.Granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares from ProQR at the public...

8:07am EDT

Foamix Pharmaceuticals prices initial public offering

Foamix Pharmaceuticals Ltd:Says pricing of its initial public offering of 6.7 mln ordinary shares at a price to the public of $6.00 per share.Grants underwriters a 30-day option to purchase up to 1,005,000 additional ordinary shares.Expected to begin trading on the NASDAQ Global Market on Sept. 18...

8:00am EDT

SIGA Technologies Inc receives Bankruptcy Court approval for first-day motions in connection with Chapter 11 case

SIGA Technologies Inc:Says that it has received Bankruptcy Court approval of 'first-day' motions that it filed on Sept. 16, ate on which it filed voluntary petition for relief under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for Southern District of New...

Wednesday, 17 Sep 2014 07:46pm EDT

GI Dynamics Inc announces that new data demonstrate robust cardiometabolic health effects of EndoBarrier therapy in obese people with and without diabetes

GI Dynamics Inc:Announces new data demonstrating clinically meaningful improvements in prevalence of metabolic syndrome, as well as a reduction in 10-year cardiovascular (CV) risk in obese patients treated with EndoBarrier Therapy.Findings from pooled analysis demonstrated that EndoBarrier Therapy...

Wednesday, 17 Sep 2014 06:29pm EDT

Veracyte Inc completes acquisition of Allegro Diagnostics Corp - Form 8-K

Veracyte Inc:Says on Sept. 16, 2014, it completed the previously announced acquisition of Allegro Diagnostics Corp.Pursuant to an agreement and plan of merger dated Sept. 4, 2014 among the company, Allegro, Full Moon Acquisition, Inc. and wholly owned subsidiary of the company (Merger Sub), Andrey...

Wednesday, 17 Sep 2014 04:09pm EDT

Flexion Therapeutics Inc announces clinical hold of FX006 Phase 2b clinical trial in Osteoarthritis of knee

Flexion Therapeutics Inc:Says United States Food and Drug Administration (FDA) informed the company yesterday that clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 2b clinical trial evaluating FX006 in patients with osteoarthritis (OA) of the knee.FX006 is a...

Wednesday, 17 Sep 2014 04:05pm EDT

Affimed Therapeutics BV announces closing of initial public offering

Affimed Therapeutics BV:Announces closing of its initial public offering of 8,000,000 common shares at an initial public offering price of $7.00 per common share.Says it has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 common shares from Affimed at the public...

Wednesday, 17 Sep 2014 01:04pm EDT

Jaguar Animal Health Inc files eighth investigational new animal drug application

Jaguar Animal Health Inc:Announces that it has submitted its eighth Investigational New Animal Drug application (INAD) with the Center for Veterinary Medicine (CVM) of the U.S. Food and Drug Administration for the treatment of insulin-resistance and metabolic syndrome in dogs.

Wednesday, 17 Sep 2014 11:00am EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.